[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "(650) 695-0677", "website": "https://www.lyell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 300, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 72, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 82734, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 65, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1021376, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 750442, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Lang J.D.", "age": 48, "title": "Advisor", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1129132, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 63, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Lee Ph.D.", "age": 47, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.47, "open": 0.47, "dayLow": 0.455, "dayHigh": 0.4846, "regularMarketPreviousClose": 0.47, "regularMarketOpen": 0.47, "regularMarketDayLow": 0.455, "regularMarketDayHigh": 0.4846, "payoutRatio": 0.0, "beta": -0.27, "forwardPE": -0.54904765, "volume": 474487, "regularMarketVolume": 474487, "averageVolume": 982743, "averageVolume10days": 615800, "averageDailyVolume10Day": 615800, "bid": 0.3335, "ask": 0.5955, "bidSize": 2, "askSize": 2, "marketCap": 136209872, "fiftyTwoWeekLow": 0.393, "fiftyTwoWeekHigh": 2.875, "priceToSalesTrailing12Months": 2232.9487, "fiftyDayAverage": 0.54654, "twoHundredDayAverage": 0.9339, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -175399440, "profitMargins": 0.0, "floatShares": 202045780, "sharesOutstanding": 295337984, "sharesShort": 5642485, "sharesShortPriorMonth": 5977013, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0191, "heldPercentInsiders": 0.13725, "heldPercentInstitutions": 0.65733004, "shortRatio": 6.59, "shortPercentOfFloat": 0.0252, "impliedSharesOutstanding": 295337984, "bookValue": 1.298, "priceToBook": 0.35531586, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -342993984, "trailingEps": -1.31, "forwardEps": -0.84, "enterpriseToRevenue": -2875.401, "enterpriseToEbitda": 0.88, "52WeekChange": -0.8185039, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 0.4612, "targetHighPrice": 1.0, "targetLowPrice": 0.6, "targetMeanPrice": 0.8, "targetMedianPrice": 0.8, "recommendationMean": 3.25, "recommendationKey": "hold", "numberOfAnalystOpinions": 2, "totalCash": 370527008, "totalCashPerShare": 1.255, "ebitda": -199302000, "totalDebt": 58968000, "quickRatio": 6.889, "currentRatio": 7.057, "totalRevenue": 61000, "debtToEquity": 15.403, "revenuePerShare": 0.0, "returnOnAssets": -0.22054, "returnOnEquity": -0.66102, "grossProfits": 61000, "freeCashflow": -67558128, "operatingCashflow": -162394000, "revenueGrowth": -0.154, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -5612.909, "financialCurrency": "USD", "symbol": "LYEL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Lyell Immunopharma, Inc.", "corporateActions": [], "postMarketTime": 1746216618, "regularMarketTime": 1746216001, "exchange": "NMS", "messageBoardId": "finmb_590661061", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "Lyell Immunopharma, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": -1.8723404, "regularMarketPrice": 0.4612, "averageDailyVolume3Month": 982743, "fiftyTwoWeekLowChange": 0.06819999, "fiftyTwoWeekLowChangePercent": 0.17353687, "fiftyTwoWeekRange": "0.393 - 2.875", "fiftyTwoWeekHighChange": -2.4138, "fiftyTwoWeekHighChangePercent": -0.8395826, "fiftyTwoWeekChangePercent": -81.850395, "earningsTimestamp": 1741723200, "earningsTimestampStart": 1746529140, "earningsTimestampEnd": 1747742400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.31, "epsForward": -0.84, "epsCurrentYear": -0.45, "priceEpsCurrentYear": -1.0248889, "fiftyDayAverageChange": -0.08534002, "fiftyDayAverageChangePercent": -0.15614597, "twoHundredDayAverageChange": -0.4727, "twoHundredDayAverageChangePercent": -0.506157, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-17", "averageAnalystRating": "3.3 - Hold", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1623936600000, "postMarketChangePercent": -2.40676, "postMarketPrice": 0.4501, "postMarketChange": -0.0111, "regularMarketChange": -0.0088, "regularMarketDayRange": "0.455 - 0.4846", "fullExchangeName": "NasdaqGS", "displayName": "Lyell Immunopharma", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]